“Switzerland has four main sources of new biotech activity,” Swiss Biotech Association CEO Michael Altorfer told Scrip. “The first source is spin-offs from academic centres in the country, the second is spin-offs from big pharma and other large conglomerates, the third is the direct creation of companies through venture builders and the fourth is companies that are founded elsewhere but have expanded or moved to set up bases in Switzerland.”
It is this fourth and final source of activity that has gained traction in recent years. “Of all the international companies that opened up a location in Switzerland last year,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
